InflaRx N.V. (IFRX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.93
• Market Cap: $63.25M
• EPS: $-0.73
• 52-Week High: $1.94
• 52-Week Low: $0.71

Market Sentiment

InflaRx N.V. currently has a Bullish sentiment score of 0.30.

About InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on the development of novel C5a inhibitors targeting the complement system for the treatment of serious inflammatory and autoimmune diseases. Headquartered in Jena, Germany, with a strategic presence in the United States, the company is advancing its innovative therapeutic pipeline led by its candidate IFX-1, currently under evaluation for hidradenitis suppurativa and other indications. InflaRx's commitment to addressing unmet...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for InflaRx N.V. and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does IFRX pay dividends?

InflaRx N.V. (IFRX) does not currently pay a regular dividend.

What is IFRX's market cap?

InflaRx N.V. (IFRX) has a market capitalization of $63.25M with a current stock price of $0.93.